Caisse de dépôt et placement du Québec ve 2. čtvrtletí koupila novou pozici v Natera za zhruba 683 000 USD. Firma zároveň oznámila výnosy 752,75 mil. USD a zisk na akcii -0,47 USD, což překonalo odhad.
Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company’s stock, valued at approximately $683,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Natera in the second quarter valued at approximately $2,962,770,000. K.J. Harrison & Partners Inc purchased a new position in Natera during the 2nd quarter worth approximately $5,117,000. Abbot Financial Management Inc. purchased a new position in Natera during the 2nd quarter worth approximately $1,537,000. Eagle Health Investments LP acquired a new stake in Natera during the 2nd quarter valued at approximately $4,302,000. Finally, UBS Group AG lifted its stake in Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after acquiring an additional 71,355 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.
Analyst Upgrades and Downgrades A number of analysts have recently weighed in on NTRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. TD Cowen boosted their target price on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research report on Friday, August 7th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $355.00 price target on shares of Natera in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $319.38.
View Our Latest Stock Analysis on Natera Natera Stock Performance Natera stock opened at $326.26 on Monday. The firm has a market cap of $47.03 billion, a PE ratio of -239.90 and a beta of 1.51. Natera, Inc. has a 12 month low of $157.43 and a 12 month high of $343.18. The stock’s 50 day simple moving average is $285.07 and its two-hundred day simple moving average is $233.78.
Natera (NASDAQ:NTRA – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same period in the previous year, the firm earned ($0.74) EPS. The business’s quarterly revenue was up 37.7% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.
Insider Activity In other Natera news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares of the company’s stock, valued at approximately $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the completion of the transaction, the chief executive officer owned 99,897 shares of the company’s stock, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 103,472 shares of company stock worth $24,960,134 in the last ninety days. Corporate insiders own 5.05% of the company’s stock.
About Natera (Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Recommended Stories Five stocks we like better than Natera Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
Natera se dohodla s Angiex na použití testu Signatera k hodnocení odpovědi na léčbu AGX101 v první fázi studie u pokročilých solidních nádorů. Test bude v čase sledovat ctDNA a doplňovat zobrazovací metody.
Key Takeaways Natera will use Signatera to assess AGX101 response in a Phase 1 trial for advanced solid tumors.Signatera will track ctDNA over time to assess whether molecular changes can complement imaging.AGX101 targets TM4SF1 in tumor cells and tumor-associated endothelial cells to deliver a cytotoxic payload. Natera (NTRA - Free Report) recently announced a collaboration with Angiex, Inc. to assess treatment response to AGX101, an investigational nuclear-delivered antibody-drug conjugate (ND-ADC), using its Signatera test. The Phase 1 trial is evaluating AGX101 in patients with unresectable, locally advanced or metastatic solid tumors.
Per management, Signatera can provide deeper insights into early biologic responses, helping to advance the understanding of the novel drug class. Natera looks forward to working with the Angiex team to generate molecular response data that could support the development of AGX101 and further the potential of this therapeutic approach.
NTRA Stock Trend Following the NewsFollowing the announcement, shares of NTRA inched up 0.1% at yesterday’s close. Year to date, the stock has gained 47.8% compared with the industry’s 4.1% growth and the S&P 500’s 11.6% rise.
The collaboration is a positive development for Natera as it expands the use of Signatera in an early-stage clinical program involving a novel cancer treatment approach. If longitudinal ctDNA monitoring demonstrates value alongside imaging, it could strengthen the utility of Signatera for treatment response assessment in advanced solid tumors. The collaboration also adds to Natera’s growing network of biopharma relationships, supporting broader adoption of its molecular residual disease (MRD) and molecular monitoring capabilities.
NTRA currently has a market capitalization of $48.79 billion.
Image Source: Zacks Investment Research
More on the NewsAGX101 is designed to target TM4SF1 and deliver a cytotoxic payload to both TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach is intended to address cancer cells as well as tumor vasculature. Signatera will be used for longitudinal circulating tumor DNA (ctDNA) monitoring to assess its potential role in monitoring treatment response throughout AGX101 therapy.
Natera’s Signatera test offers a personalized approach to measuring ctDNA and may serve as a complementary tool to radiologic evaluations. Tracking ctDNA levels over time could provide additional insights into treatment response, particularly in cases where imaging detects metabolic or structural changes that may not clearly indicate the presence of viable tumor.
Angiex co-founder and CEO Paul Jaminet, Ph.D., said AGX101 could provide a differentiated treatment option for patients with advanced solid tumors. The collaboration will assess whether longitudinal ctDNA measurements can complement imaging and offer deeper insights into treatment response.
Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global minimal residual disease testing market is predicted to be valued at $3 billion in 2026 and is expected to witness a CAGR of 13.2% through 2033.
Factors like the increasing adoption of MRD testing in oncology care, rising cancer burden, growing adoption of precision medicine and increasing use of advanced technologies like next-generation sequencing and PCR are supporting the market’s growth.
Other NewsNatera recently collaborated with Kupando Therapeutics to support a Phase 1 clinical trial evaluating circulating tumor DNA (ctDNA) dynamics in patients with advanced skin cancers. The collaboration will use Natera’s Latitude tissue-free MRD test to monitor treatment response to KUP-101, Kupando’s investigational immunotherapy targeting innate immune activation.
Natera’s MRD test, Signatera, received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer, including gastrointestinal, genitourinary, breast, skin, gynecological, head and neck, non-small cell lung cancer, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas and pan-cancer immunotherapy monitoring.
NTRA’s Zacks Rank & Key PicksCurrently, NTRA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Natera letos vzrostla o více než 37 % a její tržby ve 2. čtvrtletí stouply meziročně o 37,7 % na 752,8 milionu USD. Společnost zároveň zvýšila celoroční výhled tržeb na 2,91 miliardy USD.
During his three decades as manager of the hedge fund Duquesne Capital, Stanley Druckenmiller averaged annual returns of around 30%, beating not just the S&P 500 but also many other major hedge funds. Druckenmiller wound down his fund in 2010, converting it into a family office.This left him still highly active in the investing game, but just with his own money.
Investors can keep track of the Duquesne Family Office's positions by looking up its latest 13F filings with the Securities and Exchange Commission (SEC). Per the latest filing, submitted Aug. 14, for the quarter ended June 30, 2026, Duquesne's largest position is in Natera (NTRA +1.92%). This position, worth around $865 million, makes up 16.6% of Duquesne's overall portfolio. While the family office has continued to build up a stake in the diagnostics company, much of its value is the result of the stock's big run-up thus far in 2026.
The question now is whether more upside remains for shares, or if the stock, after its strong extended run, is at risk of an extended pullback.
Stanley Druckenmiller. Image source: Getty Images.
Natera and its recent hot run Since the start of the year, Natera has rallied by over 37%. For comparison, the S&P 500 is up just a relatively smaller 13.9% over this same time frame. Cutting-edge healthcare stocks can make volatile moves, in either direction, and that's what has happened with Natera, following a spate of positive news.
Earlier in the year, Natera shares traded sideways, even as investors remained appreciative of the company's unique strengths. This includes its dominant share of the minimal residual disease (MRD) testing market, a key segment given the strong demand for products that help detect cancer recurrence. Still, despite such strengths, valuation worries became the greater concern.
However, following two key developments, valuation worries have moved to the back burner. First, in June, shares rallied on news that Natera had received regulatory approval in Japan for its Signatera product for colorectal cancer testing. Second, and more importantly, investors reacted very positively to Natera's latest quarterly results.
As insiders sell, should you keep following Druckenmiller's lead? On Aug. 6, Natera released results for the 2026 second quarter. During this period, revenue increased 37.7% year over year, from $546.6 million to $752.8 million. The company also reported a more than 100-basis-point improvement in gross margins, as well as further progress in reaching profitability. Management also raised full-year revenue guidance, from $2.85 billion to $2.91 billion.
Today's Change
(
1.92
%) $
6.23
Current Price
$
331.30
Alongside promising financials, Natera also keeps making progress in expanding the label for its products. After the aforementioned win in Japan, the company is now seeking regulatory approval for Signatera's use as a test for muscle-invasive bladder cancer.
With the company still unprofitable, and shares trading for 16 times sales, valuation remains sky-high among medical device stocks. Near-term profit-taking, or worse, investor disappointment over further near-term developments, could lead to another sharp pullback in shares. It also doesn't help that insiders continue to sell shares, showing little interest in increasing their own personal positions.
Still, it's likely not irrational exuberance that's leading Druckenmiller to keep buying. Long-term forecasts call for double-digit revenue growth to persist, with earnings turning positive by 2028. Wait for further weakness before buying, but the long-term bull case remains intact for now.
Natera podporuje studii fáze 1 Kupando u pokročilých kožních nádorů v Německu a její test Latitude bude sledovat ctDNA v několika časových bodech. Cílem je vyhodnotit molekulární odpověď na léčbu KUP-101.
Key Takeaways Natera is supporting Kupando's Phase 1 skin cancer trial with its Latitude tissue-free MRD test.Latitude will track ctDNA at multiple timepoints to assess molecular response to KUP-101 treatment.The trial will enroll patients with advanced skin cancers at activated clinical sites in Germany. Natera (NTRA - Free Report) recently announced a collaboration with Kupando Therapeutics to support a Phase 1 clinical trial evaluating circulating tumor DNA (ctDNA) dynamics in patients with advanced skin cancers. The collaboration will use Natera’s Latitude tissue-free molecular residual disease (MRD) test to monitor treatment response to KUP-101, Kupando’s investigational immunotherapy targeting innate immune activation.
Management stated that Natera is pleased to support Kupando’s development of its first-in-class approach to innate immune activation. Latitude’s ability to evaluate ctDNA dynamics across diverse solid tumors can provide molecular insights into treatment response, potentially supporting the clinical development of KUP-101 in difficult-to-treat cancers.
Likely Trend of NTRA Stock Following the NewsShares of NTRA have declined 1.9% since the announcement on Wednesday. Year to date, shares of the company have gained 35.3% compared with the industry’s 0.6% growth and the S&P 500’s 13.2% rise.
The collaboration with Kupando Therapeutics could positively impact Natera by expanding the use of its Latitude MRD testing in early-stage clinical research. Incorporating Latitude into a Phase I trial provides an opportunity to demonstrate the assay’s ability to track ctDNA dynamics across multiple advanced skin cancers and potentially broader solid tumor types. Successful results could strengthen Natera’s position in the growing MRD and precision oncology market, support additional biopharma partnerships, and increase adoption of its testing platform in clinical trials.
NTRA currently has a market capitalization of $44.67 billion.
Image Source: Zacks Investment Research
More on the NewsThe collaboration follows the successful dosing of the first patient in Kupando’s Phase 1 trial. Following the initial dosing, Kupando’s safety committee approved continued enrollment across activated clinical sites, including leading oncology centers in Germany. The trial will generate serial molecular data to help characterize patient response to KUP-101 during treatment.
Under the collaboration, Latitude testing will be conducted at multiple timepoints during the trial to evaluate changes in ctDNA following KUP-101 treatment. The study is being conducted at activated clinical sites in Germany and will enroll patients with advanced tumors across multiple skin cancer types.
KUP-101 is designed to activate the innate immune system and induce trained immunity, offering a potentially tissue-agnostic approach across several solid tumor types. The investigational therapy is being evaluated both as a standalone treatment and in combination with other agents. By incorporating Latitude MRD testing into the trial, Kupando aims to better characterize the molecular activity of KUP-101 and generate data that may inform future clinical development.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other NewsNatera announced that its MRD test, Signatera, received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer. Signatera is certified to be used in adjuvant and surveillance settings across a broad range of cancers, including gastrointestinal, genitourinary, breast, skin, gynecological, head and neck, non-small cell lung cancer, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas and pan-cancer immunotherapy monitoring.
Natera partnered with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma. Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess MRD and treatment response during neoadjuvant, induction, adjuvant and follow-up care.
Natera partnered with Eledon Pharmaceuticals to integrate its Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed to prevent organ rejection in kidney transplantation.
NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Empowered Funds LLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 65.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,016 shares of the medical research company’s stock after selling 9,708 shares during the quarter. Empowered Funds LLC’s holdings in Natera were worth $1,003,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. Reflection Asset Management purchased a new stake in Natera during the 4th quarter valued at $29,000. Palladiem LLC purchased a new stake in shares of Natera during the 4th quarter valued at about $31,000. Horizon Investments LLC purchased a new stake in shares of Natera during the 3rd quarter valued at about $32,000. International Assets Investment Management LLC grew its stake in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust grew its stake in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the period. Institutional investors own 99.90% of the company’s stock.
Natera Price Performance NASDAQ:NTRA opened at $309.93 on Monday. Natera, Inc. has a one year low of $156.71 and a one year high of $326.03. The business has a fifty day moving average price of $263.76 and a 200-day moving average price of $226.30. The firm has a market capitalization of $44.67 billion, a price-to-earnings ratio of -227.89 and a beta of 1.51.
Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.74) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.11 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades A number of research analysts recently weighed in on NTRA shares. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Sanford C. Bernstein initiated coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Canaccord Genuity Group set a $375.00 price target on Natera in a research note on Friday, August 7th. Finally, Wells Fargo & Company lifted their price objective on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.
View Our Latest Research Report on NTRA
Insider Activity In other Natera news, insider John Fesko sold 295 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the sale, the insider owned 183,774 shares in the company, valued at approximately $49,249,594.26. This trade represents a 0.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by insiders.
Natera Company Profile (Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Further Reading Five stocks we like better than Natera The Metals Company’s Big Bet Now Comes Down to a License OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings Meta and Tesla Are Rebounding From Oversold Levels—Now What? AMG’s Alternatives Boom Powers Record Growth Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
Natera zvýšila výhled po rekordních objemech Signatera, které ve 2. čtvrtletí přesáhly 280 000 kusů. Firma zároveň uvedla, že tržby rostly, marže se zlepšily a ztráta se zúžila.
3 Under-the-Radar Healthcare CompaniesNatera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
Speaking at the Canaccord Genuity Growth Conference, Brophy said Natera raised its outlook following a quarter in which volume performance was broad-based. He described organ health momentum as “very strong” and said women’s health posted high-single-digit year-over-year growth despite typically experiencing seasonal sequential declines.
Get Natera alerts:
Women’s Health Momentum and Product Updates
Myriad Genetics Sees Stock Surge with Hereditary Cancer TestsBrophy attributed part of the women’s health performance to uptake of Natera’s Fetal Focus offering, which launched several quarters ago and continued to gain traction through the second quarter. He also highlighted the June launch of a new version of the Panorama non-invasive prenatal testing assay.
The updated Panorama test is designed to offer greater sensitivity, particularly in cases with low fetal fraction, an area that Brophy said has historically been challenging for non-invasive prenatal testing. Because the launch occurred in early June, he said it was not a significant driver of second-quarter results but could support women’s health performance during the remainder of the year.
While Brophy characterized the quarter as exceptional, he said his typical framework for women’s health is mid-single-digit volume growth, with the opportunity for faster revenue growth if Natera can increase reimbursement realization for covered services.
Record Signatera Volumes
The company’s oncology business, led by its Signatera molecular residual disease and recurrence-monitoring test, reached more than 280,000 units during the quarter. Brophy said the company added approximately 34,000 units sequentially, compared with a prior quarterly record increase of about 25,000 units.
He noted that first-quarter Signatera volumes were somewhat affected by weather-related disruptions. Natera estimates that roughly 2,000 to 4,000 units that otherwise may have been received in the first quarter arrived later, contributing to the magnitude of the second-quarter sequential increase. Even excluding that effect, Brophy called the quarter an “absolute blowout.”
He cited several drivers of Signatera’s growth:
Continued generation of clinical outcomes data for Signatera and molecular residual disease testing.
FDA approval related to Signatera’s use in muscle-invasive bladder cancer.
Inclusion in National Comprehensive Cancer Network guidelines for muscle-invasive bladder cancer in June.
The full operational impact of a commercial expansion completed around April.
Brophy said newer offerings, including Genome and Latitude, accounted for only a small portion of total Signatera volume. However, he said their availability broadens the company’s product menu and may enhance Signatera’s positioning with physicians.
Coverage, International Expansion and Laboratory Investment
Natera expects to continue pursuing reimbursement coverage on a tumor-type-by-tumor-type basis, Brophy said. He described the company’s interactions with MolDX, Medicare’s molecular diagnostic services program, as positive and said Natera has now achieved coverage across much of the critical mass of common tumor types. The company is now working on additional, less common cancers, he said.
In Japan, Natera has received PMDA approval for Signatera and has submitted for bladder cancer coverage following its approval in colorectal cancer. Brophy said the company remains on track for an early 2027 Japanese launch. The next steps include discussions with Japanese agencies regarding the number of reimbursed testing time points and pricing, which he expects to be addressed in the second half.
The company is also expanding laboratory capacity. Brophy said Natera’s Austin, Texas, laboratory is expected to become the world’s largest genomics laboratory once its current expansion is completed. First-half capital expenditures increased to approximately $85 million from about $45 million in the prior-year period. He said the elevated spending level is not expected to represent ongoing maintenance capital expenditures, which he estimated at closer to $60 million annually.
Early Cancer Detection Investment
Brophy said Natera remains ambitious in early cancer detection, where its FIND-CRC study is approaching enrollment completion at up to 40,000 patients. He emphasized the expense and complexity of bringing a blood-based early cancer detection assay to market, estimating that a company may need to spend roughly $500 million before selling its first test when clinical development and regulatory work are included.
Rather than immediately building a large commercial team, Brophy said Natera expects to use a phased approach, deploying an initial group of sales representatives in selected geographies and expanding based on early results and returns on invested capital.
He acknowledged that early cancer detection spending is currently weighing on the company’s overall profit profile because the program is generating operating expenses without revenue or gross profit. Still, he said Natera is seeing losses narrow while continuing to invest in research and development, Signatera clinical studies and commercial growth initiatives.
Looking internationally, Brophy said Natera sees significant demand for Signatera in Europe following IVDR approval. He said reimbursement opportunities will need to be evaluated country by country and use case by use case, while noting that the company is conducting clinical studies in Europe, including CIRCULATE-France.
About Natera (NASDAQ:NTRA)Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Natera Right Now?Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Matthew Rabinowitz z Natera prodal 731 akcií za 267,99 USD za kus, ale šlo o automatický prodej kvůli daňovým odvodům z vestingu RSU. Po transakci stále drží zhruba 2,3 milionu akcií přímo a 4 000 nepřímo.
Matthew Rabinowitz, the executive chairman of Natera, Inc. (NTRA -1.16%), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.
Transaction summaryMetricValueShares sold (directly held)731Transaction value$195,901Post-transaction shares (directly held)2,275,394Post-transaction shares (indirectly held)4,000Post-transaction value$616.26 millionTransaction value based on SEC Form 4 weighted average sale price ($267.99); post-transaction value based on the August 3 market close ($270.36).
Key questionsWhat was the motivation for this disposition?
The sale was non-discretionary and performed specifically to satisfy tax withholding and remittance obligations triggered by the vesting of restricted stock units. This arrangement was established under a Rule 10b5-1(c) plan dated January 31, 2025, and does not reflect a discretionary change in the executive's investment thesis.How significant is the remaining equity position?
Matthew Rabinowitz continues to hold a substantial interest in the company, with roughly 2.3 million shares held directly and an additional 4,000 shares held indirectly through a spouse. This total beneficial ownership is valued at approximately $616.26 million as of the August 3 market close.What is the recent performance context for the stock?
As of the August 3 transaction date, Natera had delivered a one-year total return of roughly 100%. The stock was priced at $275.19 as of the August 4 market close, representing a market capitalization of $39.4 billion.Company OverviewMetricValueShare Price (as of market close 2026-08-04)$275.19Market Capitalization$39.4 billionRevenue (TTM)$2.7 billionNet Income (TTM)-$192.3 millionCompany SnapshotNatera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, per-test pricing, and reimbursement from insurance carriers and government programs.Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale and maintains a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.
What this transaction means for investorsSet against what he owns, this sale rounds to nothing. Rabinowitz sold 731 shares while holding roughly $616 million of Natera stock, so the fraction that left to cover a tax bill is a rounding error on a co-founder's fortune — which is a billionaire-level fortune in this case, according to Forbes. The shares vested and were withheld automatically under a plan set in early 2025, which is about as far from a discretionary call as an insider filing gets. He sold on August 3, days before the company reported, so the timing predates the news that moved the stock.
That report was a strong one. Natera grew second-quarter revenue about 38% to $753 million, beat expectations handily, and raised its full-year outlook, driven by its Signatera cancer test, whose clinical volume climbed 56%. Gross margin reached about 65%, up on better pricing and efficiency. So what’s the verdict for long-term investors? A co-founder parting with a few hundred shares to satisfy taxes, days before a quarter like that, really tells you nothing except that the calendar and the tax code did their usual work. More importantly, the firm is firing on all cylinders, and momentum is on its side.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.
Šéf klinické diagnostiky Natera Solomon Moshkevich prodal 3 410 akcií za 906 000 USD v rámci plánu 10b5-1 kvůli daním. Po transakci drží asi 129 000 akcií.
Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NTRA -1.16%), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value$906,000Shares sold3,410Post-transaction shares (directly held)129,000Post-transaction value$34.88 millionTransaction value based on SEC Form 4 weighted average sale price ($265.58); post-transaction value based on the August 3 market close ($270.36).
Key questionsWhat was the primary driver of this transaction?
The disposition was non-discretionary, executed to cover tax withholding obligations related to the vesting of restricted stock units, and does not reflect the insider's view on the stock. The sale was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2024, in accordance with written instructions dated January 31, 2025.How much equity does the insider retain in the company?
Following the sale, Solomon Moshkevich retains a direct interest of about 129,000 shares, representing a 0.09% ownership stake. This remaining position is valued at $34.88 million as of the August 3 market close.What is the recent market context for the stock?
Natera has seen an over 100%% one-year return as of the August 3 transaction date. As of the August 4 market close, shares were priced at $275.19. Company OverviewMetricValueShare Price (as of market close 2026-08-04)$275.19Market Capitalization$39.4 billionRevenue (TTM)$2.7 billionNet Income (TTM)-$192.3 millionCompany SnapshotNatera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, pricing per test, and reimbursement from insurance carriers and government programs.Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale with a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.
What this transaction means for investorsMoshkevich runs the part of the company that actually powered the quarter, since clinical diagnostics is home to Signatera, the cancer test behind Natera's surge, and that makes his filing more interesting than many other others who filed reports this past week even though the sale itself is pure mechanics, essentially tax withheld on vesting shares under a plan set well in advance. He sold before earnings and kept a stake worth about $35 million, so nothing here signals doubt.
Meanwhile, the business delivered the quarter's standout numbers. Natera's molecular residual disease testing, the Signatera franchise, grew volume about 56% to 283,000 units, helping lift second-quarter revenue roughly 38% to $753 million and prompting a $100 million guidance raise. Signatera also picked up fresh regulatory wins in the period, including U.S. companion-diagnostic approval in bladder cancer to deepen its foothold in oncology. With shares more than doubling this past year and nearing records, the market is pricing in continued execution, which amounts to greater risk, but the firm certainly has momentum on its side.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.
Natera, Inc. (NTRA) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDT
Company Participants
Mike Brophy - Chief Financial Officer
Steve Chapman - CEO & Director
Solomon Moshkevich - President of Clinical Diagnostics
Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer
Conference Call Participants
Puneet Souda - Leerink Partners LLC, Research Division
Daniel Brennan - TD Cowen, Research Division
David Westenberg - Piper Sandler & Co., Research Division
Daniel Markowitz - Evercore ISI Institutional Equities, Research Division
Noah Kava - Jefferies LLC, Research Division
Kallum Titchmarsh - Morgan Stanley, Research Division
Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to Natera's Second Quarter 2026 Earnings Conference Call. [Operator Instructions]
I will now hand the conference over to Michael Brophy, Chief Financial Officer. Michael, please go ahead.
Mike Brophy
Chief Financial Officer
Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our second quarter of 2026. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and our Chief Medical Officer. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.
Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results, opportunities and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results. We caution you that such statements reflect
Natera ve 2. čtvrtletí 2026 zvýšila tržby o 37,7 % na 752,8 milionu USD a zúžila čistou ztrátu na 67,0 milionu USD. Zároveň zvedla celoroční výhled tržeb na 2,85 až 2,91 miliardy USD.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026.
Recent Financial Highlights
Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. Generated a gross margin1 of 64.5% in the second quarter of 2026, compared to a gross margin1 of 63.4% in the second quarter of 2025. Excluding revenue true-ups, second quarter non-GAAP gross margin2 improved 50 basis points over the first quarter of 2026. Processed approximately 1,043,900 tests in the second quarter of 2026, compared to approximately 853,100 tests in the second quarter of 2025, an increase of 22.4%. Processed approximately 296,700 oncology tests in the second quarter of 2026, compared to approximately 188,800 in the second quarter of 2025, an increase of 57.2%. Clinical molecular residual disease (MRD) oncology units grew 34,000 units over the first quarter of 2026, the largest sequential increase to-date. Increased cash by approximately $3.6 million3 during the second quarter of 2026. Raised 2026 annual revenue guidance by $100 million at the midpoint, from $2.74 billion - $2.82 billion to $2.85 billion - $2.91 billion. “We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology volumes,” said Steve Chapman, chief executive officer of Natera. “We also reached several landmark milestones in the last few months: SignateraTM achieved three significant regulatory approvals, Medicare coverage expanded for ProsperaTM, and we launched a major enhancement to our PanoramaTM NIPT.”
Second Quarter Ended June 30, 2026 Financial Results
Total revenues were $752.8 million in the second quarter of 2026 compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. The increase in revenues was driven by an increase in volume and average selling price improvements.
Natera processed approximately 1,043,900 tests in the second quarter of 2026, including approximately 1,030,100 tests accessioned in its laboratory, compared to approximately 853,100 tests processed, including approximately 839,300 tests accessioned in its laboratory, in the second quarter of 2025.
In the second quarter of 2026, Natera recognized revenue on approximately 985,500 tests for which results were reported to customers in the period (tests reported), including approximately 972,000 tests reported from its laboratory, compared to approximately 812,900 tests reported, including approximately 799,900 tests reported from its laboratory, in the second quarter of 2025, an increase of 21.2% from the prior period.
Gross profit1 for the three months ended June 30, 2026 and 2025 was $485.2 million and $346.6 million, respectively, representing a gross margin1 of 64.5% and 63.4%, respectively. Natera had higher gross margin1 in the second quarter of 2026 primarily as a result of higher revenues and continued progress in reducing cost of revenues associated with tests processed. There was also a change in estimate of approximately $52.3 million in the second quarter of 2026 in revenue accrual as compared to $45.3 million in the second quarter of 2025. Changes in estimates for the three months ended June 30, 2026 and 2025 increased revenue and, as a result, increased gross margin1 and gross profit1 by 2.7% and $52.3 million, and by 3.3% and $45.3 million, respectively.
Gross margin1 for the three months ended March 31, 2026 was 64.7%. Excluding the change in estimates in revenue accruals of approximately $52.3 million and $61.0 million during the three months ended June 30, 2026 and March 31, 2026, respectively, Natera’s non-GAAP gross margin2 increased by approximately 0.5% sequentially.
Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the second quarter of 2026 was $555.3 million, compared to $457.0 million in the same period of the prior year, an increase of 21.5%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses. Amortization of acquired intangible assets for the second quarter of 2026 was $5.7 million. No such amortization occurred in the second quarter of 2025.
Loss from operations for the second quarter of 2026 was $75.8 million compared to $110.4 million for the same period of the prior year.
Natera’s net loss for the second quarter of 2026 was $67.0 million, or ($0.47) per diluted share, compared to a net loss of $100.9 million, or ($0.74) per diluted share, in the second quarter of 2025. Weighted average shares outstanding were 143.3 million in the second quarter of 2026 compared to 136.4 million for the same period in the prior year.
At June 30, 2026, Natera held approximately $1,091.5 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025. As of June 30, 2026, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
Financial Outlook
Natera anticipates 2026 total revenue of $2.85 billion to $2.91 billion; 2026 gross margin1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.125 billion to $1.225 billion; research and development costs to be $800 million to $900 million; and cash flow to be positive.
Test Volume Summary
Unit
QTD 2026
QTD 2025
Definition
Tests processed
1,043,900
853,100
Tests accessioned in our laboratory plus units processed outside of our laboratory
Tests accessioned
1,030,100
839,300
Test accessioned in our laboratory
Tests reported
985,500
812,900
Total tests reported
Tests reported in our laboratory
972,000
799,900
Total tests reported in our laboratory less units reported outside of our laboratory
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Conference Call Information
Event:
Natera’s Second Quarter Financial Results Conference Call
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our market opportunity, anticipated products and launch schedules, reimbursement coverage, product costs, and gross margins, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and our strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.
These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; unless otherwise indicated, all financial data for the current and prior quarters are unaudited and subject to adjustment in connection with the completion of our quarterly and annual financial reporting processes; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.
We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.
We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.
References:
Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues. Excluding the change in estimates in revenue accruals of approximately $52.3 million and $61.0 million during the three months ended June 30, 2026 and March 31, 2026, respectively, Natera’s non-GAAP gross margin increased by approximately 0.5% sequentially. Includes GAAP cash, cash equivalents and restricted cash. Natera, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except shares)
June 30,
2026
December 31,
2025
(1)
Assets
Current assets:
Cash, cash equivalents and restricted cash
$
1,091,502
$
1,076,140
Accounts receivable, net of allowance of $6,526 in 2026 and $8,018 in 2025
Natera podala v Japonsku u PMDA žádost o schválení testu Signatera jako doprovodné diagnostiky pro svalově invazivní rakovinu močového měchýře. Žádost navazuje na nedávné schválení v USA pro MIBC a v Japonsku pro kolorektální karcinom.
Follows Signatera’s recent U.S. FDA approval in MIBC and Japanese PMDA approval in CRC
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx).
The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country’s first PMDA-approved molecular residual disease (MRD) test.
The MIBC application is supported by data from IMvigor011, a randomized, double-blind Phase 3 clinical trial. It also builds on recent milestones for Signatera in MIBC: the U.S. FDA’s approval of Signatera™ CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq®); and a Category 1 recommendation for Signatera MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for Bladder Cancer.
Bladder cancer affects more than 34,000 people in Japan each year.1 Globally, approximately 20–25% of newly diagnosed bladder cancers are muscle-invasive.2 MIBC is a more aggressive form of the disease, associated with higher recurrence risk and treatment complexity.
“Signatera is a proven tool in bladder cancer management, and this submission reflects our commitment to bringing precision diagnostics to patients in Japan,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. “We look forward to engaging with the PMDA and to improving outcomes for patients around the world.”
Notes
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
References
World Cancer Research Fund International. Bladder cancer statistics. Accessed June 26, 2026. https://www.wcrf.org/preventing-cancer/cancer-statistics/bladder-cancer-statistics/ Gakis G. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur. Urol. Focus. 2020;6(4):632-638. About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Studie v JAMA Dermatology ukázala, že Signatera lépe než AMERK předpovídá návrat Merkelova karcinomu. Zachytila relaps častěji, se senzitivitou 90 % vs 55 % a dříve o 5,1 měsíce vs 2,1 měsíce.
Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.
MCC is a rare but aggressive skin cancer that recurs in approximately 40% of patients.1 Despite its severity, clinicians have lacked a reliable, universal biomarker to guide surveillance. The AMERK test has been a widely used monitoring tool, but its utility is limited: it can only be used in the roughly 50% of MCC patients whose tumors are virus-positive, and its accuracy diminishes after immunotherapy exposure or multiple recurrences.2-3 Signatera’s clinical validation has been published across all MCC patients, irrespective of viral status, leading to inclusion in NCCN Guidelines as a recommendation for surveillance monitoring.
This published study is a retrospective analysis of a prospective, multicenter, head-to-head comparison of Signatera and AMERK testing in 169 patients with MCC. Key findings include:
Superior predictive power: The Signatera test was a significantly stronger predictor of recurrence than AMERK (HR difference = 6.6; p < 0.001), with higher hazard ratios, higher positive predictive value (PPV), and higher negative predictive value (NPV).Higher Sensitivity: Signatera detected recurrence more frequently than AMERK with a sensitivity of 90% vs 55%, respectively.Longer Lead Time: In patients where recurrence was detected by both tests, Signatera detected recurrence earlier than AMERK with a median lead time of 5.1 months vs. 2.1 months, respectively.“For years, AMERK had been our best available tool, but its inability to function in virus-negative patients and after immunotherapy has been a recognized limitation,” said Lisa Zaba, M.D., Ph.D., associate professor of dermatology and director of the Merkel cell carcinoma multidisciplinary clinic at the Stanford University School of Medicine, and corresponding author of the study. “These data demonstrate that Signatera can give clinicians a more precise and earlier signal across all patients, enabling more proactive management of this challenging disease.”
“Signatera MRD testing outperformed AMERK across every key measure in this study — sensitivity, hazard ratios, predictive values, and lead time to detection,” said Alexey Aleshin, M.D., MBA, corporate chief medical officer and general manager, oncology, at Natera. “Signatera was shown to be a more universally reliable biomarker for MCC surveillance, particularly because it retains its accuracy in both virus-positive and virus-negative disease and after exposure to immunotherapy.”
References
McEvoy AM, Lachance K, Hippe DS, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382-389. doi:10.1001/jamadermatol.2021.6096Paulson KG, Lewis CW, Redman MW, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer. 2017;123(8):1464-1474. doi:10.1002/cncr.30475Miller DM, Shalhout SZ, Wright KM, et al. The prognostic value of the Merkel cell polyomavirus serum antibody test: a dual institutional observational study. Cancer. 2024;130(15):2670-2682. doi:10.1002/cncr.35314About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Duquesne Family Office Stanleyho Druckenmillera měla v prvním čtvrtletí 2026 největší pozici v Naterě za těsně pod 613 miliony USD, což představovalo 18,1 % portfolia. Natera zároveň v 1. čtvrtletí 2026 zvýšila tržby o 39 % na 697 milionů USD.
He's a retired hedge fund manager, but people still want to know what billionaire Stanley Druckenmiller is doing with his money. The answer? Investing in the medical diagnostic company Natera (NTRA 0.31%).
As of the first quarter of 2026, Natera was the top holding of the Duquesne Family Office, which manages Druckenmiller's private wealth. It accounted for 18.1% of the portfolio's holdings, and the stake was worth slightly under $613 million at the time.
The genetic testing company may not be as well known as Nvidia or get as much attention, but surprisingly, Natera has quietly returned three times more than the chipmaker over the past 12 months.
Stanley Druckenmiller. Image source: Getty Images.
Druckenmiller keeps betting big on Natera Duquesne provides quarterly filings showing what it bought and sold, but it isn't required to explain its investment decisions.
Still, as the medical testing market is rapidly growing, it makes sense as to why Druckenmiller and his family office have been aggressively building a position in Natera. According to Grand View Research, the global genetic testing market was valued at only $11.7 billion in 2024, but is expected to reach $39.3 billion by 2030. And the global cancer diagnostics market is even bigger, expected to climb from $119.8 billion in 2025 to $191.1 billion by 2033.
Natera has a lot of opportunities within those markets, as it specializes in cell-free DNA testing and has testing for oncology, organ health, and women's health. It also offers testing for rare diseases. One product growth source for the company, in particular, has been through oncology testing. Last year, Natera increased its processed oncology tests by 51.6% from over 528,000 in 2024 to more than 800,000 in 2025. In the first quarter of 2026, it also saw a 50%+ increase in processed oncology tests.
In addition, Natera offered its shareholders even more bullish news in June, as its Signatera test became the first approved molecular residual disease test approved for patients with colorectal cancer in Japan. Signatera is expected to launch in Japan by the end of 2026.
Strong results continue into 2026 In 2025, Natera generated $2.3 billion, which was a 35.9% increase from 2024. That's on the back of increased testing; Natera processed 3.5 million total tests in 2025, a 15% increase from the number of tests processed in 2024.
Thus far, Natera is continuing to ride that wave of momentum. In the first quarter of 2026, it exceeded one million processed tests in a quarter for the first time. It also reported revenue of $697 million, a 39% increase, and Natera also boosted the midpoint of its full-year sales guidance by $120 million.
Today's Change
(
-0.31
%) $
-0.87
Current Price
$
276.50
Should you follow Druckenmiller's lead into Natera? Natera continues to show that demand for its testing is increasing, and shareholders have been rewarded with a rising stock price. As of this writing, the Natera stock price is up over 19%, and while it may not make investing headlines like Nvidia, Natera is performing better than the chipmaker. Over the last 12 months, the Natera stock price has been up more than 72%, while the Nvidia stock price has climbed slightly above 24%.
It's also a company that analysts generally view favorably, with 19 out of 22 saying Natera is a buy.
That said, Natera is also an unprofitable company. In 2025, it reported a net loss of $208.2 million, up from a net loss of $190.4 million in 2024. It's also continuing to invest heavily in research and development (R&D), with its R&D costs climbing from $129.1 million in Q1 2025 to $210.7 million in Q1 2026.
Overall, Natera can reward shareholders who are comfortable with an investment with high-reward potential but also increased risk. It's a leader in the medical diagnostics space and continues to report impressive revenue growth.
But owning Natera also means accepting the company's unprofitability, which may continue for some time. Druckenmiller appears comfortable with the risk associated with his Natera investment, but that's not reason alone for retail investors to own the stock.
Natera oznámila, že Signatera získala certifikaci jako zařízení třídy C podle nařízení EU IVDR jako první personalizovaný MRD test pro solidní nádory v EU. Certifikace má usnadnit zavádění nových studií a udržet dostupnost v EU po roce 2028.
Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR).
The IVDR represents one of the world’s most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platform — including the assay, specimen collection kit, and associated software — underwent a comprehensive review against some of the most stringent standards in the medical industry, including evidence of analytical and clinical validity, as well as quality system management.
IVDR certification reduces the lead time and regulatory overhead for launching new clinical trials, and it ensures that Natera can continue offering Signatera to EU patients after the IVDD transition deadline in 2028.
Under this certification, Signatera is indicated for use in the adjuvant and surveillance settings across gastrointestinal malignancies, genitourinary malignancies, non-small cell lung cancer, head and neck cancer, breast cancer, skin cancer, gynecological malignancies, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas, and pan-cancer immunotherapy monitoring.
Certification was supported by extensive clinical and analytical evidence demonstrating Signatera’s performance across multiple tumor types and clinical settings. It follows two significant regulatory milestones for the Signatera portfolio: in June 2026, Signatera received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for patients with colorectal cancer; and in May 2026, the U.S. Food and Drug Administration approved Signatera™ CDx as a companion diagnostic for patients with muscle-invasive bladder cancer.
“MRD testing is redefining how we assess recurrence risk and guide treatment decisions for patients with cancer,” said Julien Taieb, M.D., Ph.D., head of the gastroenterology and gastrointestinal oncology department at the Université Paris-Cité. “This certification for Signatera is an important milestone as it will enhance access to personalized MRD testing for patients across Europe within a more rigorous regulatory framework.”
“Achieving IVDR certification is a key milestone in Natera’s plan to bring Signatera MRD testing to Europe,” said Solomon Moshkevich, president, clinical diagnostics at Natera. “Backed by extensive clinical evidence across multiple cancer types, this builds on our recent regulatory approvals in both the United States and Japan.”
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Natera se spojí s Aveta Biomics a do globální studie fáze 3 LA-HNSCC zapojí test Signatera pro sledování MRD a odpovědi na léčbu. Studie může zahrnout asi 826 pacientů.
Key Takeaways Natera partnered with Aveta to integrate Signatera into a global Phase 3 LA-HNSCC trial.Signatera will assess MRD and treatment response across neoadjuvant to follow-up care.The trial may enroll 826 patients globally, with enrollment expected in the second half of 2026. Natera (NTRA - Free Report) recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess molecular residual disease (MRD) and treatment response during neoadjuvant, induction, adjuvant and follow-up care.
Management noted that growing clinical evidence continues to demonstrate the value of Signatera for MRD detection in head and neck cancer. The company believes its collaboration with Aveta on the AVTA 30-01 trial will further demonstrate Signatera’s potential to advance the field and improve patient care.
Likely Trend of NTRA Stock Following the NewsShares of NTRA have lost 0.3% since the announcement on Monday. Year to date, the stock has gained 18.5% against the industry’s 2.3% decline. The S&P 500 has risen 9.7% in the same timeframe.
The partnership with Aveta Biomics is a positive development for Natera as it expands the clinical use of Signatera in a global Phase 3 registrational trial. Successful validation of Signatera for MRD monitoring and treatment response in head and neck cancer could strengthen its clinical evidence and support wider adoption. Over time, the collaboration could enhance Natera’s position in precision oncology while creating opportunities for biopharma partnerships centered on MRD-guided treatment strategies.
NTRA currently has a market capitalization of $39.00 billion.
Image Source: Zacks Investment Research
More on the NewsAPG-157 is Aveta’s first-in-class oral immunotherapy designed to benefit both immune-hot and immune-cold tumors in LA-HNSCC. The therapy has received FDA Fast Track and Orphan Drug Designations for this indication. The Phase 3 study builds on Phase 2 results that demonstrated favorable safety, evidence of tumor control, deep molecular responses and promising event-free survival outcomes.
The trial is expected to enroll approximately 826 patients across North America, Europe, Asia-Pacific and Australia, with patient enrollment to begin in the second half of 2026. It will include separate randomized cohorts for patients with resectable and unresectable locally advanced disease, with both treatment and control arms. Signatera will serve as a secondary endpoint to generate insights into disease recurrence and therapeutic response through circulating tumor DNA (ctDNA) monitoring to assess MRD.
Head and neck cancer affects roughly 950,000 people worldwide each year, and recurrence remains a significant cause of mortality despite advances in surgery, radiation and immunotherapy. This collaboration further expands Natera’s clinical evidence in head and neck cancer, following the positive results from the recently concluded Phase 2 SINERGY trial, which supported the use of Signatera MRD-guided monitoring in this disease setting.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other NewsNatera recently announced a collaboration with CytoDyn to evaluate ctDNA dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer (mCRC) program.
In May, Natera announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.
Natera received the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer.
NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
BrightSpring Health, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Natera a Aveta Biomics uzavřely partnerství pro globální fázi 3 registrační studii AVTA 30-01 s APG-157 u lokálně pokročilého spinocelulárního karcinomu hlavy a krku. Do studie se zapojí Signatera pro sledování molekulární odpovědi a minimální reziduální nemoci (MRD).
Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).
APG-157 is Aveta's first-in-class oral immunotherapy intended to expand the benefits of immunotherapy to both immune-cold and immune-hot tumors in patients with LA-HNSCC. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication.
AVTA 30-01 builds upon previously reported Phase 2 clinical data of APG-157 monotherapy in demonstrating favorable safety, evidence of tumor-control, deep molecular responses, and encouraging event-free survival outcomes. The trial will incorporate serial Signatera testing to assess molecular residual disease (MRD) and treatment response throughout therapy and follow-up. Circulating tumor DNA (ctDNA) has emerged as one of the most promising approaches for detecting MRD and identifying recurrence earlier than conventional imaging alone.
Approximately 826 patients are expected to be enrolled across North America, Europe, Asia-Pacific, and Australia. The study includes separate randomized cohorts for resectable and unresectable locally advanced disease, each with treatment and control arms, and Signatera will be a secondary endpoint. The trial is expected to begin enrollment in 2H’26.
Global annual incidence of head and neck cancer is approximately 950,000,1 and disease recurrence remains a major cause of mortality despite advances in surgery, radiation therapy, and immunotherapy.
“Patients with locally advanced head and neck cancer continue to face substantial risks of recurrence despite aggressive treatment,” said Parag Mehta, Ph.D., founder and chief executive officer of Aveta Biomics. “We believe APG-157 has the potential to transform treatment by activating anti-tumor immunity in both immune-cold and immune-hot tumors. Incorporating serial Signatera testing into AVTA 30-01 will allow us to further validate the ctDNA findings observed in Phase 2 while generating molecular response data that will advance the understanding of treatment benefits for patients and strengthen the regulatory submission.”
This study adds to the evidence Natera continues to generate in head and neck cancer. The company recently announced a successful readout of the prospective Phase 2 SINERGY trial, supporting Signatera MRD-guided treatment in this histology.
“Growing evidence continues to demonstrate the value of Signatera MRD detection in head and neck cancer,” said Eric Matthews, general manager, biopharma, Natera. “We’re pleased to partner with Aveta on AVTA 30-01 to demonstrate how Signatera has the potential to advance the field and improve care for patients.”
References
Sun H, et al. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2025 Sep 25;15:1665019.About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
About Aveta Biomics
Aveta Biomics is a clinical-stage immuno-oncology company advancing first-in-class oral therapies designed to reprogram the tumor microenvironment and expand the benefits of immunotherapy to patients with immune-cold cancers. The company’s lead candidate, APG-157, has received FDA Fast Track and Orphan Drug Designations for head and neck squamous cell carcinoma and is in a global phase 3 registrational trial. APG-157 is also being evaluated across additional oncology indications including high-grade adult glioma and oral dysplasia. For more information, visit www.avetabiomics.com.
Forward-Looking Statements (for Natera)
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Forward-Looking Statements (for Aveta)
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those regarding the impact of the Fast Track Designation, the progress of our clinical trials, potential regulatory approvals, the development and commercial success of our drug candidates, and our strategic goals, reflect our current expectations and involve risks and uncertainties. Actual results may differ materially due to factors such as our ability to advance drug candidates through development and regulatory approval, clinical trial outcomes, competition, and economic conditions. Words like “may,” “will,” “could,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. We caution you not to place undue reliance on these statements, which speak only as of the date they are made. As a private company, Aveta Biomics is under no obligation to publicly update or revise any forward-looking statements to reflect new information or future events, except as required by applicable law.
Natera získala v Japonsku schválení pro Signatera u kolorektálního karcinomu a plánuje komerční spuštění do konce roku 2026, pokud padne konečné rozhodnutí o cenách. O podporu prodeje se postará SRL Inc.
The precision medicine company expects to launch Signatera commercially in Japan by the end of 2026, pending final pricing decisions.
The approval marks a key milestone in Natera’s international oncology expansion.
More than 150,000 people are diagnosed with colorectal cancer each year in Japan, making it one of the country’s most common cancers and highlighting the need for personalized treatment strategies.
Clinical Evidence And Medical Society Support Back ApprovalThe cancer test company said findings from the GALAXY clinical trial supported regulatory clearance.
The study showed that patients who tested MRD-positive following surgery experienced substantial benefit from adjuvant chemotherapy, while MRD-negative patients did not appear to benefit from the treatment.
The GALAXY trial analyzed 2,240 samples, making it one of the largest prospective studies evaluating MRD testing in resectable colorectal cancer.
The study forms part of the broader CIRCULATE-Japan platform, which involves thousands of patients and more than 150 institutions across Japan.
SRL To Lead Commercialization Efforts Across JapanCommercial rollout of Signatera in Japan will be supported by SRL Inc., Japan’s largest reference laboratory and a member of H.U. Group Holdings.
As Natera’s exclusive business partner in Japan, SRL will help expand access to personalized MRD testing through its nationwide laboratory network.
On Tuesday, the National Comprehensive Cancer Network (NCCN) recognized Natera’s Signatera technology for muscle-invasive bladder cancer.
The recognition marks the third NCCN guideline recommendation for circulating tumor DNA (ctDNA) testing, which could enhance treatment protocols for patients, reflecting positively on Natera’s market position and growth potential.
NTRA Stock Price Activity: Natera shares were up 10.29% at $258.92 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by Michael Vi via Shutterstock
Market News and Data brought to you by Benzinga APIs
